In this article, we break down the Top 5 Heavily Shorted Small-Cap and Mid-Cap Stocks to Buy Today. For investors looking for the complete list, you can explore our full report on the Top 10 Heavily Shorted Small-Cap and Mid-Cap Stocks to Buy Today.
5. Intellia Therapeutics Inc. (NASDAQ:NTLA)
Short Float: 39.19%
Market Cap: $1.92 Billion
Stock Upside Potential: 53.97%
Intellia Therapeutics, Inc. (NASDAQ: NTLA) takes the No. 5 spot on this list of the heavily shorted mid-cap and small-cap stocks to buy today, and the story here is a classic Wall Street tug-of-war between dilution fears and clinical promise. With a short float of 39.19%, NTLA is one of the most heavily shorted biotech stocks in this ranking. That level of bearish pressure tells investors that the market is not fully convinced, especially after the company announced a sizable follow-on equity offering. But it also means that if sentiment turns, NTLA could quickly become one of the more closely watched short squeeze stocks, CRISPR stocks, and biotech stocks with upside potential.
On May 13, H.C. Wainwright reiterated a Buy rating on Intellia Therapeutics but lowered its price target to $25 from $30. The price target cut was tied mainly to dilution concerns after the company announced a $180 million follow-on equity offering involving 16.7 million shares priced at $10.75 per share. That offering represented an 18.6% discount to the stock’s closing price after the announcement, which naturally gave short sellers more reason to press the bearish case. The offering was originally planned at $150 million but was upsized to $180 million, giving Intellia more gross proceeds but also raising the issue of shareholder dilution.
That is the part the bears love. In biotech, dilution is never a small matter because many clinical-stage companies do not yet have meaningful product revenue. They need cash to fund trials, regulatory work, manufacturing, and pipeline development, but every new share sale can pressure existing shareholders. That is why many investors searching for the best small-cap biotech stocks, high short interest stocks, and gene editing stocks to buy now often look closely at a company’s balance sheet and cash runway before getting excited about the science.
But Intellia is not just another speculative biotech name with a vague laboratory story. The company remains one of the more important clinical-stage biotechnology companies developing potentially curative treatments using CRISPR/Cas9 gene editing technology. Its goal is bold: permanently modify disease-causing genes in the human body through a single course of treatment. That is the kind of scientific ambition that can attract both long-term biotech investors and aggressive traders looking for the next major breakthrough in genetic medicine stocks.
The biggest reason H.C. Wainwright stayed bullish despite the dilution issue was Intellia’s top-line results from the Phase 3 lonvo-z trials. According to the provided data, 62% of patients became attack-free and therapy-free with no adverse events. For a clinical-stage biotech stock, that type of result matters because strong clinical data can change the entire investment conversation. Dilution may hurt in the near term, but successful late-stage data can create a pathway toward regulatory submission, possible approval, and future commercialization.
Intellia is also planning a regulatory submission for a potential first-half 2027 U.S. launch. That gives NTLA a clear catalyst timeline, which is exactly what many biotech traders look for when screening most shorted stocks to buy now, small-cap stocks with big upside, and biotech stocks under pressure with possible catalysts. The stock’s 53.97% upside potential adds more interest to the story, especially because 35 hedge funds were holding shares, showing that institutional investors have not walked away from the name despite the heavy short float.
The simple version is this: NTLA is risky, diluted, and heavily shorted, but it is also backed by real clinical ambition and late-stage data that could matter. For investors who can handle volatility, Intellia Therapeutics remains one of the more fascinating gene-editing stocks in the small-cap and mid-cap universe.
Click next to see the following stock...
